Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lithium carbonate
Drug ID BADD_D01303
Description Lithium has been used to treat manic episodes since the 19th century[A176642]. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].
Indications and Usage Lithium is used as a mood stabilizer, and is used for treatment of depression and mania. It is often used in bipolar disorder treatment.
Marketing Status Prescription; Discontinued
ATC Code N05AN01
DrugBank ID DB14509
KEGG ID D00801
MeSH ID D016651
PubChem ID 11125
TTD Drug ID D04UUH
NDC Product Code 72789-173; 68462-222; 71610-557; 0220-3128; 0054-2531; 31722-546; 68462-224; 0054-0021; 71335-0120; 64117-256; 50090-1470; 46708-303; 70518-0437; 51079-180; 0054-8527; 0054-8526; 0054-2527; 62559-280; 0054-0020; 50090-2799; 0378-1450; 68084-655; 51079-142; 0378-1300; 68462-221; 0054-4527; 70518-0904; 50090-2959; 46708-304; 68084-640; 71335-1067; 0220-3129; 63629-7730; 66039-947; 58118-0545; 70518-0668; 62332-013; 72789-174; 50090-2754; 73309-248; 63629-1916; 64980-278; 82388-001; 0054-2526; 70518-2312; 63629-8282; 63629-1917; 55154-4920; 68428-481; 62332-014; 62756-430; 0054-8528; 70518-0608; 64980-205; 42291-496; 62332-015; 70518-2345; 68462-220; 50090-3918; 23155-763; 68788-7716; 0220-3131; 63187-304; 70518-1753; 71335-1006; 46708-305; 46708-148; 70518-2086; 62332-148; 31722-544; 63629-7903; 68462-223; 72789-171; 72789-172; 50090-3917; 0615-8302; 70518-2699; 0054-8531; 39345-5104; 43063-901; 70518-1434; 31722-545
Synonyms Lithium Carbonate | Carbonate, Lithium | Dilithium Carbonate | Carbonate, Dilithium | Lithane | Lithium Bicarbonate | Bicarbonate, Lithium | Lithobid | Lithonate | CP-15,467-61 | CP 15,467 61 | CP15,46761 | Micalith | NSC-16895 | NSC 16895 | NSC16895 | Priadel | Quilinorm-retard | Quilinorm retard | Quilinormretard | Eskalith | Lithotabs
Chemical Information
Molecular Formula CLi2O3
CAS Registry Number 554-13-2
SMILES [Li+].[Li+].C(=O)([O-])[O-]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Nephrogenic diabetes insipidusVasopressin V2 receptorP48044Not AvailableNot Available
Renal aplasiaVasopressin V2 receptorP48044Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hallucination, visual19.10.02.0040.000818%Not Available
Headache17.14.01.001--
Hepatitis C11.05.06.004; 09.01.09.0050.000818%Not Available
Hypercalcaemia14.04.01.003; 05.04.01.0020.004088%
Hyperglycaemia14.06.02.002; 05.06.02.0020.000818%
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkinesia17.01.02.008--Not Available
Hypermagnesaemia14.04.02.002--
Hypernatraemia14.05.04.0010.004906%
Hyperparathyroidism05.04.01.0010.014718%
Hyperparathyroidism primary05.04.01.0050.004088%Not Available
Hyperreflexia17.02.01.0020.002044%Not Available
Hypersensitivity10.01.03.003--
Hypersensitivity vasculitis24.05.02.012; 23.06.02.005; 10.02.02.017; 01.01.04.008--Not Available
Hypersomnia19.02.05.001; 17.15.01.0010.000818%
Hypertension24.08.02.001--
Hyperthermia12.05.01.002; 08.05.01.0010.000427%Not Available
Hyperthyroidism14.11.01.011; 05.02.02.0010.002453%
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hyperventilation22.02.01.006; 19.01.02.004--Not Available
Hypokalaemia14.05.03.0020.001635%
Hyponatraemia14.05.04.0020.001227%
Hyporeflexia17.02.01.0030.001635%
Hypotension24.06.03.0020.004088%
Hypothyroidism14.11.01.012; 05.02.03.0010.004906%
Hypotonia15.05.04.008; 17.05.02.0020.001635%Not Available
Hypovolaemia14.05.05.0020.000818%Not Available
Incontinence20.02.02.004; 17.05.01.006; 07.01.06.0110.000818%Not Available
Infection11.01.08.002--Not Available
Insomnia17.15.03.002; 19.02.01.0020.003271%
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 11 Pages